Article
ABCC2 rs2273697 is an independent determinant of tacrolimus intra-patient variability during the first year after kidney transplantation.
International journal of clinical pharmacy - 1 Aug 2026
You Jia, Liu Hongxia, Yang Yunyun, Fu JiaZhao, Sui Mingxing, Zhao Wenyu, Yuan Zhilong, Ma Tao, Wang Zhuo, Wang Xuebin
Abstract excerpt
INTRODUCTION: Tacrolimus is a critical immunosuppressive agent in kidney transplantation, but its pharmacokinetic variability, especially intra-patient variability (IPV), can lead to suboptimal outcomes. Genetic polymorphisms in CYP3A5 and ABCC2 may influence tacrolimus metabolism and transport, affecting dosing requirements and IPV. However, their combined impact during the first year after kidney...
Topics
Join the communities discussing this publication.
